EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction

Akuzike Kalizang'oma, Todd D Swarthout, Thandie S Mwalukomo, Arox Kamng'ona iD, Comfort Brown, Jacquline Msefula, Hayley Demetriou, Jia Mun Chan, Lucy Roalfe, Uri Obolski, Jose Lourenço, David Goldblatt und 3 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Akuzike Kalizang'oma und 14 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Mucosal Pathogens Research Unit, Research Department of Infection, Division of Infection and Immunity, University College London, London, United…. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Streptococcus pneumoniae, Pneumococcal Infections, Serogroup. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Streptococcus pneumoniae serotype 3 remains a problem globally. Malawi introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2011, but there has been no direct protection against serotype 3 carriage. We explored whether vaccine escape by serotype 3 is due to clonal expansion of a lineage with a competitive advantage.

Methods

The distribution of serotype 3 Global Pneumococcal Sequence Clusters (GPSCs) and sequence types (STs) globally was assessed using sequences from the Global Pneumococcal Sequencing Project. Whole-genome sequences of 135 serotype 3 carriage isolates from Blantyre, Malawi (2015–2019) were analyzed. Comparative analysis of the capsule locus, entire genomes, antimicrobial resistance, and phylogenetic reconstructions were undertaken. Opsonophagocytosis was evaluated using serum samples from vaccinated adults and children.

Results

Serotype 3 GPSC10-ST700 isolates were most prominent in Malawi. Compared with the prototypical serotype 3 capsular polysaccharide locus sequence, 6 genes are absent, with retention of capsule polysaccharide biosynthesis. This lineage is characterized by increased antimicrobial resistance and lower susceptibility to opsonophagocytic killing.

Conclusions

A serotype 3 variant in Malawi has genotypic and phenotypic characteristics that could enhance vaccine escape and clonal expansion after post-PCV13 introduction. Genomic surveillance among high-burden populations is essential to improve the effectiveness of next-generation pneumococcal vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal VaccinesStreptococcus pneumoniaePneumococcal InfectionsSerogroupPhylogenyBacterial CapsulesHumansMalawiAdultWhole Genome SequencingChild, PreschoolChildVaccines, ConjugateMaleGenome, BacterialFemaleYoung AdultInfantGenotypeCarrier State

Stichwörter der Autor:innen

Streptococcus pneumoniaeAfricacapsulepneumococcal conjugate vaccineserotype 3

Substanzen

Pneumococcal Vaccines13-valent pneumococcal vaccineVaccines, Conjugate

Autor:innen und Institutionen

  • NIHR Mucosal Pathogens Research Unit, Research Department of Infection, Division of Infection and Immunity, University College London, London, United Kingdom.
  • Pneumonia and Meningitis Pathogens Associate Research Group, Malawi-Liverpool-Wellcome Research Programme, Blantyre, Malawi.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • School of Medicine and Oral Health, Kamuzu University of Health Sciences, Blantyre, Malawi.
  • School of Life Sciences and Allied Health Professionals, Kamuzu University of Health Sciences, Blantyre, Malawi.
  • Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.

ORCID-Profile: Arox Kamng'ona, Neil French, Robert S Heyderman

Förderung

  • Medical Research Council
  • Wellcome Trust

Zitieren

APA

Kalizang'oma, A., Swarthout, T. D., Mwalukomo, T. S., Kamng'ona, A., Brown, C., Msefula, J., Demetriou, H., Chan, J. M., Roalfe, L., Obolski, U., Lourenço, J., Goldblatt, D., Chaguza, C., French, N., & Heyderman, R. S. (2024). Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae040

Vancouver

Kalizang'oma A, Swarthout TD, Mwalukomo TS, Kamng'ona A, Brown C, Msefula J, et al. Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae040

BibTeX
@article{Kalizangoma2024,
  author = {Kalizang'oma, Akuzike and Swarthout, Todd D and Mwalukomo, Thandie S and Kamng'ona, Arox and Brown, Comfort and Msefula, Jacquline and Demetriou, Hayley and Chan, Jia Mun and Roalfe, Lucy and Obolski, Uri and Lourenço, Jose and Goldblatt, David and Chaguza, Chrispin and French, Neil and Heyderman, Robert S},
  title = {Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae040}
}
Kostenlos starten →